Product Development

In Vitro and In Vivo Testing

Experienced, in-house testing

Alira Health offers a broad range of in vitro and in vivo testing services, led by the expertise of our experienced in-house scientists.

Access and design the right test

With multiple methodologies available for evaluation of your product, our scientists will help you select or design a test that meets your needs:
  • Biofilm studies and antimicrobial formulations
  • Genetic and enzymatic profiling (qPCR, ELISA, FRET, immunostaining)
  • Biomechanical testing and wound healing models, 3D tumor models and 3D bioprinting

In vitro and in vivo testing options

Our expertise covers the performance of individualized pharmaceutical drug tests to analyze efficacy on target cells of systemic therapy for both in vitro and in vivo.

In vitro testing

In vitro testing is an important alternative to animal testing, and Alira Health offers a range of in vitro testing options. Our in vitro testing laboratories offer cell-based biological and non-biological methods for safety and toxicity testing from a range of industries. In vitro testing services include:

  • Cell models for inflammation, migration, 3D tumor, and apoptosis
  • Gene Expression (qPCR) and Immunocytochemistry
  • Microbiology and Biofilm Models
  • Fluorescent and colorimetric microplate assays

In vivo testing

Alira Health scientists are experienced in conducting in vivo testing for the purposes of efficacy and safety. In vivo testing services include:

  • Animal models in wound repair and regeneration
  • Infection and biofilm models
  • Mouse tumor survival models

Why choose Alira Health?

As our partner, you’ll work closely with our team of experienced scientists to leverage their:

  • More than three decades experience in preclinical models for wound repair and regeneration
  • Leading expertise in biofilm and preclinical infection models
  • Rapid turnaround and responsiveness to client requirements and deadlines

Related news

Research & Development
Publications June 9, 2021
EU Supply Integrity Guidelines
Check out Alira Health's latest publication, “EU Supply Integrity Guidelines”. In the document, best practices for European distribution and supply integrity management are highlighted(...)
Research & Development
Publications May 27, 2021
Buffers – Navigating New Demands On Downstream Raw Materials
The COVID-19 pandemic has put unusual pressures on the supply and demand of raw materials required for the production and purification of biologics. A specific concern for the biomanufacturing(...)
Research & Development
Publications April 26, 2021
Recombinant Human Polyclonal Antibodies to Treat Disease
Congratulations to Alira Health’s Steven Chamow, PhD, Senior Vice President, CMC and founder of Chamow & Associates, and to Bryan Monroe and Chuck Olson, Senior Consultants, on their(...)
Research & Development
News March 15, 2021
Alira Health Welcomes Nikole Siegmund, Vice President, Preclinical
BOSTON, USA – Alira Health (www.alirahealth.com), a leading international healthcare and life sciences advisory firm, is pleased to announce that Nikole Siegmund has joined the firm(...)
Research & Development
Publications March 9, 2021
A Primer on Potency Assays for Release of Biologics
A key criterion in determining the quality of a biologic product is whether it has maintained its biological activity or “potency.”
Advanced Analytics Regulatory Research & Development
News November 20, 2020
Alira Health’s Ventures Portfolio Company, X-COR Therapeutics, Closes Initial $2.6M Funding Round
Alira Health congratulates X-COR Therapeutics for closing a $2.6M seed financing to continue developing its novel extracorporeal carbon dioxide removal device toward clinical trials.(...)

Our locations around the globe

Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.